Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.45 |
| ▸ | PPARA | Q07869 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052101 | 0.84 | PPARG (0.61) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL7927937 | 0.84 | PPARG (0.46) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| Darglitazone SCHEMBL9436449 | 0.83 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| Darglitazone SCHEMBL20125582 | 0.83 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| Darglitazone SCHEMBL37497 | 0.83 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL7723286 | 0.82 | PPARG (0.42) | PPARGPPARAFFAR1KDM4EPPARD | |
| Darglitazone SCHEMBL674635 | 0.82 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL9097431 | 0.81 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL8030739 | 0.80 | PPARG (0.59) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL6052111 | 0.80 | PPARG (0.60) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647289-A1 | Peroxisome proliferator-activated receptor gamma ligand eluting medical device | Medtronic Vascular, Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| EP-1236478-B1 | Peroxisome proliferator-activated receptor gamma ligand eluting medical device | MEDTRONIC VASCULAR INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20020127263-A1 | Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device | MEDTRONIC AVE, INC. | 2002-09-12 | — | — | US | claimed |
| EP-1236478-A1 | Peroxisome proliferator-activated receptor gamma ligand eluting medical device | Medtronic Ave, Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| US-6172089-B1 | 2,4-THIADOLIDINEDIONE INSULIN SENSITIVITY ENHANCER MIXTURE WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| EP-0984780-A1 | USE OF THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME AND GESTATIONAL DIABETES | WARNER-LAMBERT COMPANY (US) | 2000-03-15 | — | — | EP | claimed |
| US-5972944-A | ADMINISTERING TO A PATIENT SUFFERING FROM ANOVULATION A THERAPEUTICAL AMOUNT OF TROGLITAZONE | WARNER-LAMBERT COMPANY (US) | 1999-10-26 | — | — | US | claimed |
| US-5965584-A | insulin sensitivity enhancer such as pioglitazone in combination with a biguanide such as metformin | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-12 | — | — | US | claimed |
| WO-1998055121-A1 | USE OF THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME AND GESTATIONAL DIABETES | WARNER-LAMBERT COMPANY (US) | 1998-12-10 | — | — | WO | claimed |
| US-11021751-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8846315-B2 | Disease risk factors and methods of use | ZINFANDEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | ZINFANDEL PHARMACEUTICALS, INC. | 2011-07-07 | — | — | US | disclosed |
| EP-2292268-A1 | Pharmaceutical composition for use in treatment of diabetes | Takeda Pharmaceutical Company Limited (JP) | 2011-03-09 | — | — | EP | disclosed |
| EP-0851757-A2 | A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | disclosed |
| WO-1997018811-A1 | A METHOD OF TREATING MYOTONIC DYSTROPHY | WARNER-LAMBERT COMPANY (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997005875-A2 | A METHOD OF REDUCING THE AMOUNT OF EXOGENOUS INSULIN ADMINISTERED TO A PATIENT HAVING NONINSULIN-DEPENDENT DIABETES MELLITUS | WARNER-LAMBERT COMPANY (US) | 1997-02-20 | — | — | WO | disclosed |
| EP-0749751-A2 | Pharmaceutical composition for use in tteatment of diabetes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166185-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885PPARA 1499/4885CYP3A4 1186/4885 |
| US-20150073022-A1 | DISEASE RISK FACTORS AND METHODS OF USE | TSG101, TOMM40, TOMM70 | PPARG 1229/4885PPARA 1499/4885CYP3A4 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.